

Cipla – Recall of albuterol inhalation aerosol

• On July 7, 2023 the <u>FDA announced</u> a consumer level recall of six lots of Cipla's <u>albuterol</u> inhalation aerosol because of a complaint for one inhaler where leakage was observed through the inhaler valve. Out of an abundance of precaution, six lots manufactured using the same lot of valves are being recalled.

Product Description	Lot Number (Exp Date)	NDC Number
Albuterol sulfate inhalation aerosol, 90 mcg (200 metered inhalation)	IB20045 (11/23); IB20055 (11/23); IB20056 (11/23); IB20057 (11/23); IB20059 (11/23); IB20072 (11/23)	69097-142-60

- Albuterol is indicated for the treatment and prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise induced bronchospasm.
- There is a reasonable probability that failure to deliver the recommended dose of albuterol to treat the respiratory symptoms of an acute asthma exacerbations such as wheezing coughing, shortness of breath and bronchospasms, due to device defect, may be life-threatening.
- To date, Cipla has not received any reports of adverse events related to the recalled albuterol.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using the recalled drug products.
- Anyone with the affected lot on hand should stop use and distribution and return to place of purchase.
- Contact Cipla at 1-844-247-5287 or by email at <u>cipla.cs@cipla.com</u> for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.